Stereotaxis to Present at Cowen 5th Annual FutureHealth Conference
June 18 2020 - 9:05AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, today
announced that David Fischel, Chairman and CEO, will present at the
Cowen 5th Annual FutureHealth Conference on Thursday, June 25, 2020
at 10:15 am EDT.
Hosted by Josh Jennings, Senior Health Care
Research Analyst of Cowen and Company, Mr. Fischel will lead a
panel discussion titled, The Powerful Combination of Advanced
Imaging & Robotics. The discussion will focus on the value of
integrating high quality diagnostic imaging with robotics to
improve patient care and modernize interventional surgery.
Highlights will include the recent integration with Acutus
Medical’s advanced cardiac mapping technology and Stereotaxis’
other efforts to digitize the cath lab.
“In previous discussions we’ve primarily focused
on the mechanistic benefits of robotics in electrophysiology,” says
Mr. Fischel. “I look forward to focusing more on the central role
of robotics in digitizing interventional medicine and Stereotaxis’
efforts to advance digital surgery with image guided therapies,
telemedicine, automation and big data insights.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute “forward-looking” statements, usually containing the
words “believe,” “estimate,” “project,” “expect” or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to continue to manage expenses
and cash burn rate at sustainable levels, continued acceptance of
the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare policy in the United
States, including changes in government reimbursement of
procedures, dependence upon third-party vendors, timing of
regulatory approvals, the impact of the recent coronavirus
(COVID-19) pandemic and our response to it, and other risks
discussed in the Company's periodic and other filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside
of the Company's control. In addition, these orders and commitments
may be revised, modified, delayed or canceled, either by their
express terms, as a result of negotiations, or by overall project
changes or delays.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024